Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial.
T. Dejgaard,C. Frandsen,10 Authors,H. U. Andersen
2016 · DOI: 10.1016/S2213-8587(15)00436-2
The Lancet Diabetes and Endocrinology · 131 Citations
TLDR
The efficacy and safety of the GLP-1 receptor agonist liraglutide as an add-on therapy to insulin for overweight adult patients with type 1 diabetes and its use in this study is registered with ClinicalTrials.gov, number NCT01612468.